Increased Plasma Interleukin-32 Expression in Patients with Neuromyelitis Optica

详细信息    查看全文

• 作者：Honghao Wang (1) (2)
  Kai Wang (1)
  Conghui Wang (3)
  Fangcheng Xu (1)
  Wei Qiu (2)
  Xueqiang Hu (2) (4)
  
• 关键词：IL ; 32 ; neuromyelitis optica ; multiple sclerosis ; IL ; 6 ; IL ; 17
• 刊名：Journal of Clinical Immunology
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：33
• 期：3
• 页码：666-670
• 全文大小：168KB
• 参考文献：1. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Na-kashima I, Weinshenker BG. A serum auto-antibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-2. CrossRef
  2. Wang H, Wang K, Zhong X, Qiu W, Dai Y, Wu A, Hu X. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012;32:1007-1. CrossRef
  3. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535-4. CrossRef
  4. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;12:51450-461.
  5. Barnett MH, Sutton I. Neuromyelitis optica: not a multiple sclerosis variant. Curr Opin Neurol. 2012;25:215-0. CrossRef
  6. Turner-Brannen E, Choi KY, Arsenault R, El-Gabalawy H, Napper S, Mookherjee N. Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1. J Immunol. 2011;186:7127-5. CrossRef
  7. Steinman L, Conlon P. Antigen specific immunotherapy of multiple sclerosis. J Clin Immunol. 2001;21:93-. CrossRef
  8. Park YE, Kim GT, Lee SG, Park SH, Baek SH, Kim SI, Kim JI, Jin HS. IL-32 aggravates synovial inflammation and bone destruction and increases synovial natural killer cells in experimental arthritis models. Rheumatol Int. 2012;PubMed PMID: 22527134.
  9. Meyer N, Christoph J, Makrinioti H, Indermitte P, Rhyner C, Soyka M, Eiwegger T, Chalubinski M, Wanke K, Fujita H, Wawrzyniak P, Bürgler S, Zhang S, Akdis M, Menz G, Akdis C. Inhibition of angiogenesis by IL-32: possible role in asthma. J Allergy Clin Immunol. 2012;129:964-3. CrossRef
  10. Na SJ, So SH, Lee KO, Choi YC. Elevated serum level of interleukin-32α in the patients with myasthenia gravis. J Neurol. 2011;258:1865-0. CrossRef
  11. Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LA. Interleukin-32: A predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 2012;PubMed PMID: 22878344.
  12. Jung MY, Son MH, Kim SH, Cho D, Kim TS. IL-32gamma induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production. J Immunol. 2011;186:6848-9. CrossRef
  13. Noh J, Noh G. Allergen-specific. Responses of CD19high and CD19low B Cells in Non-IgE mediated food allergy of late eczematous reactions in atopic dermatitis: presence of IL-17- and IL-32-producing regulatory B cells (Br17 & Br32). Inflamm Allergy Drug Targets. 2012;11:320-. CrossRef
  14. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-. CrossRef
  15. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-02. CrossRef
  16. Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, van den Berg WB, Joosten LA. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis. 2011;70:660-. CrossRef
  17. Xu Q, Pan X, Shu X, Cao H, Li X, Zhang K, Lu J, Zou Y, Li X, Liu H, Zhang Y, Yang D, Ning Q, Shen G, Li G. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver. J Infect. 2012;65:336-2. CrossRef
  18. Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA. Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 2012;287:5733-3. CrossRef
  19. Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev. 2007;6:131-. CrossRef
  20. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim SH. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A. 2005;102:16309-4. CrossRef
  21. Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, Hu X. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation. 2012;19:304-. CrossRef
  22. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108:3701-. CrossRef
  23. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, Adorini L. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol. 1999;163:2403-.
  24. Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 2011;32:232-. CrossRef
  25. Misu T, Takahashi T, Nakashima I, Fujihara K. Biomarkers in neuromyelitis optica. Brain Nerve. 2012;64:525-5.
  26. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72:53-4. CrossRef
  27. Wang H, Dai Y, Qiu W, Lu Z, Peng F, Wang Y, Bao J, Li Y, Hu X. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011;18:1313-. CrossRef
  28. Li Y, Wang H, Long Y, Lu Z, Hu X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2011;234:155-0. CrossRef
  
• 作者单位：Honghao Wang (1) (2)
  Kai Wang (1)
  Conghui Wang (3)
  Fangcheng Xu (1)
  Wei Qiu (2)
  Xueqiang Hu (2) (4)
  
  1. Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
  2. Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
  3. Department of Geriatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
  4. MS Clinical Research Center, Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou, Guangdong, China
  
• ISSN：1573-2592

文摘

Purpose Neuromyelitis optica (NMO) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The pathogenesis of NMO remains unclear. IL-32 is emerging as a critical molecule in the pathophysiology of immune-mediated chronic inflammatory diseases. Whether IL-32 levels are elevated in NMO patients is unclear. We aimed to determine whether IL-32 levels are elevated in NMO patients and explore its relationship with IL-6, IL-17, and Expanded Disability Status Scale (EDSS) scores. Methods Plasma IL-32α, IL-6 and IL-17A were measured by enzyme-linked immunosorbent assay in NMO (n--6), MS (n--3) and 22 healthy controls. Results We found IL-32α levels were higher in NMO patients compared with MS (p--.020) and healthy controls (p--.00001). IL-32α levels were increased in MS patients compared with controls (p--.009). IL-32α positively correlated with IL-6 and IL-17A levels and EDSS scores in NMO patients. Conclusions In summary, plasma IL-32α levels are associated with inflammatory responses in NMO patients.